Peter Karachunski reports the findings from a real-world study showing that disease-modifying therapies have favorable safety and effectiveness profiles in infants with spinal muscular atrophy identified through newborn screening (3:40).
Funding for independent interviews at WMS 2022 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.